Using Prostate-specific Antigen To Diagnose Prostate Cancer: Sailing in Uncharted Waters
Authors: Patrick C. Walsh
Journal: Annals of Internal Medicine (1993)

Editorials1 November 1993Using Prostate-specific Antigen To Diagnose Prostate Cancer: Sailing in Uncharted WatersPatrick C. Walsh, MDPatrick C. Walsh, MDThe Johns Hopkins Hospital, Baltimore, MD 21287-2101.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-9-199311010-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In the United States, a man is diagnosed with prostate cancer every 3 minutes and death from the disease occurs every 15 minutes. This year, 35 000 men in the United States will die of prostate cancer, approximately 1 of every 4 who develop the disease. Although the number of deaths from other illnesses has decreased, the mortality from prostate cancer has risen during the last 5 years by 2.5% to 3% per year.To reduce the number of deaths from prostate cancer, there are four approaches: primary prevention, early diagnosis, effective treatment of curable disease, and improved management of ...References1. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993; 119:914-23. Google Scholar2. Walsh PC. Benign prostatic hyperplasia. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr, eds. Campbell's Urology. 6th edition. Philadelphia: W.B. Saunders; 1992:1009. Google Scholar3. Optenberg SA, Thompson IM. Economics of screening for carcinoma of the prostate. Urol Clin North Am. 1990; 17:719-37. Google Scholar4. Stormont TJ, Farrow GM, Myers RP, Blute ML, Zincke H, Wilson TM, et al. Clinical stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology. 1993; 41:3-8. Google Scholar5. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. A multicenter evaluation of PSA and digital rectal examination (DRE) for early detection of prostate cancer in 6,374 volunteers (Abstract). J Urol. 1993; 149:412A. Google Scholar6. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992; 267:2215-20. Google Scholar7. Catalona WJ, Snow PB. Artificial neural networks for predicting prostate cancer: a pilot study. Program of the 107th Meeting of the American Association of Genitourinary Surgeons; 1993:39. Google Scholar8. Oesterling JE, Chute CG, Jacobsen SJ, Guess HA, Panser LA, Johnson CL, et al. Longitudinal changes in serum PSA (PSA velocity) in a community-based cohort of men (Abstract). J Urol. 1993; 149: 412A. Google Scholar9. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA.1992; 267:2191-6. Google Scholar10. Walsh, PC. Editorial comment on Johansson, J-E, et al. High 10-year survival rate in patients with early, untreated prostatic cancer. J Urol.1992; 148:1353. Google Scholar11. Adolfsson J, Steineck G, Whitmore WF Jr. Recent results of management of palpable clinically localized prostatic cancer: A review and commentary. Cancer.1993; 72:310-22. Google Scholar12. Tubiana M, Malaise EP. Growth rate and cell kinetics in human tumours: some prognostic and therapeutic implications. In: Symington T, Carter RL, eds. Scientific Foundations of Oncology. Chicago:Year Book Medical Publishers; 1976:126-36. Google Scholar13. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res.1992; 52:3323-28. Google Scholar Author, Article, and Disclosure InformationAuthors: Patrick C. Walsh, MDAffiliations: The Johns Hopkins Hospital, Baltimore, MD 21287-2101.Corresponding Author: Patrick C. Walsh, MD, Department of Urology, Marburg 134, The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287-2101. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoProstate Cancer Screening: What We Know and What We Need To Know Barnett S. Kramer , Martin L. Brown , Philip C. Prorok , Arnold L. Potosky , and John K. Gohagan Metrics Cited byThe Distribution of PSA Age-Specific Profiles in Healthy Irish Men between 20 and 70Prostate Cancer Screening: A Review of the Evidence with Clinical Practice ImplicationsAge-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at riskA discussion of general prostate cancer screening versus targeted diagnosis in younger menDefining an Optimum PSA-Based Screening Strategy for Young MenAge-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patientsPopulation Screening for Prostate Cancer and Emerging Concepts for Young MenPopulation Screening for Prostate Cancer and Early Detection in High-risk African American Men**The opinion and assertions contained herein are the private views of the author and are not to be considered as reflecting the views of the US Army or the Department of Defense.Promoting informed decision making about prostate cancer screeningProstate-specific antigen levels in young white and black men 20 to 45 years oldPart II. Prostate cancer screeningPredictors of Interest in Prostate-Specific Antigen Screening and the Impact of Informed ConsentIs there an easier way to determine whether early detection of prostate cancer reduces mortality?Prostate-specific antigen-detected prostate cancer (Stage T1c): An analysis of whole-mount prostatectomy specimensDiagnosis and Treatment of Benign Prostatic Hyperplasia Practice Patterns of Primary Care PhysiciansProspective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigenTHE USE OF PROSTATE-SPECIFIC ANTIGEN AND FREE/TOTAL PROSTATE-SPECIFIC ANTIGEN IN THE DIAGNOSIS OF LOCALIZED PROSTATE CANCERAge-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black MenUtility of chest radiography and cystoscopy in the evaluation of patients with localized prostate cancerProspective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSAScreening for Prostate Cancer with Prostate-Specific Antigen — An Examination of the EvidenceValue of Prostate Specific Antigen in Early Diagnosis of Prostate Cancer: Study of Men Born in 1913Value of Prostate Specific Antigen in Early Diagnosis of Prostate CancerProstate cancer screening and prevention: “realities and hope”Should medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategiesShould medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? part I: Framing the debateThe mammography and prostate-specific antigen controversiesSurgical management of prostate cancer. Contemporary results with anatomic radical prostatectomyEvaluation of age-specific normal ranges for prostate-specific antigenInterleukin-6: A candidate mediator of human prostate cancer morbidityProblem of Prostate CancerThe Clinical Usefulness of Prostate Specific Antigen: Update 1994 1 November 1993Volume 119, Issue 9Page: 948-949KeywordsCancer screeningCancer treatmentGenetic diseasesHormonal therapyLongitudinal studiesMortalityProstate cancerProstate diseasesRadical prostatectomySpecificity ePublished: 15 August 2000 Issue Published: 1 November 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...